A n estimated 26 730 men in the United States will die from prostate cancer in 2017. 1 The lethal form of the disease generally occurs when prostate cancer reaches a state of castration resistance and widely metastasizes. The androgen receptor (AR) axis remains functional in this advanced state by several mechanisms, including mutation, overexpression, and ligand-independent activation. 2 Effective new drugs that target the AR-signaling axis are in development. Two such agents, abiraterone acetate and enzalutamide, have been approved for treating advanced prostate cancer based on demonstration of improved survival. [3] [4] [5] [6] As AR-directed treatments become more widely available, improved biomarkers of AR axis activity are needed to optimize patient selection, tumor detection, and monitoring of treatment response and/or progression. We have focused on molecular imaging of men with metastatic castrationresistant prostate cancer (mCRPC), as described by Scher and colleagues. 7 We report baseline imaging characteristics of 133 patients with mCRPC who were examined with dual positron emission tomography/computed tomography (PET/CT) imaging using 2-flouro- We hypothesized that the imaging phenotypes for these radiotracers would be clinically relevant on both a lesion and patient basis by providing insights into the heterogeneous biology of mCRPC that identify patient subsets with distinct prognostic features for better treatment selection and monitoring.
Methods

Patient Selection
Patients with progressive mCRPC were prospectively enrolled to undergo dual firmed adenocarcinoma of the prostate and progressive disease based on either a minimum of 3 rising prostate-specific antigen (PSA) levels taken 1 week apart, with the last result being at least 2 ng/mL or new or progressive soft tissue and/or bone disease confirmed on combined CT/magnetic resonance imaging or bone scan ( Figure 1) . Patients who had not undergone orchiectomy had to continue androgen deprivation therapy (<50 ng/dL) to maintain castrate levels of testosterone. 7 The clinical protocol for this study was reviewed and approved by Memorial Sloan Kettering Cancer Center's institutional review board. The participants provided written informed consent. There was no financial compensation.
PET/CT Imaging Protocol
PET/CT imaging was performed as previously described 8, 9 and was temporally scheduled to serve as a baseline prior to entry into contemporary clinical drug trials for AR-directed therapy in which the patients were separately enrolled. [ 
Key Points
Question Would molecular imaging with positron emission tomography for androgen receptors using fluorodihydrotestosterone F 18 and glycolysis using 2-fluoro-2-D-deoxyglucose F 18 identify biochemical characteristics of castration-resistant prostate cancer that would be predictive for prognosis?
Findings In a cohort study of 133 patients, clinically relevant heterogeneity affecting prognosis was found in imaging phenotypes for androgen receptor expression and glycolysis on a lesion-by-lesion and individual patient basis.
Meaning Prognosis of patients with metastatic castration-resistant prostate cancer is adversely affected by easily observed positron emission tomography-based molecular imaging biomarkers (eg, total lesion numbers detected per patient, high 2-fluoro-2-D-deoxyglucose F 18 uptake of individual lesions, and the pattern of androgen receptor and glycolysis lesion phenotypes) within individual patients.
immediately before injection of 370 MBq (10 mCi) after a 4-to 6-hour fast (serum glucose levels <200 lesion-by-lesion analysis was performed using PET/CT volume computer-assisted reading workstation (GE Healthcare), according to previously described methodology in which lesions are measured quantitatively with maximum standardized uptake value (SUVmax) and qualitatively (confidence scale, 0-4) with a background correction factor to optimize objectivity and interobserver agreement with respect to the imaging detectability threshold. 10 Paired PET/CT data for 
Lesion Description
We developed a shorthand notation for PET/CT scandetermined molecular imaging phenotypes of 1 for positive or detected and 0 for negative or undetected. 
Patient Description
We grouped patients into 4 categories based on imaging characteristics and phenotypes ( Figure 2) . Given that all patients had at least 1 AR 1 /Glyc 1 lesion, the 4 groups were (1) 
Statistical Analysis
Our goal was to assay imaging phenotype on a lesion-bylesion and per-patient basis to determine biologic and clinically relevant PET/CT features that could serve to enhance our understanding of mCRPC biology in terms of metastatic distribution, estimate prognosis, improve trial design (patient selection in particular), and possibly estimate response to AR-signaling inhibitor (ARSi) therapy. An important companion goal was to develop and validate methodology that allows for analysis of multiple lesions per patient, which is commonplace in mCRPC. A sub-aim of this process was to optimize the application of information from lesion biopsies to provide estimates of accuracy of AR and glycolysis imaging in this patient group. Standard statistical approaches were described in the protocol for comparing lesions seen on multiple imaging modalities. The following parameters were correlated with survival: SUVmax for [
F]-FDHT, SUVmax for [
18 F]-FDG, and number of lesions per patient. These parameters were first used as continuous variables and then as dichotomous variables using median split. In addition, 4 distinct groups were created and tested for significant associations with survival. All associations between categorical variables and survival were evaluated using the log-rank test, and associations between continuous variables and survival were evaluated using Cox proportional hazards regression. Several [
F]-FDG and [
18 F]-FDHT PET/CT parameters were compared and correlated with standard clinical variables using both graphical methods (eg, scatterplots) and statistical metrics (eg, correlation coefficients). These analyses of agreement were performed on a lesional basis. Prognostic values of imaging parameters were assessed using standard survival analysis methods, such as Kaplan-Meier estimation for survival probabilities, log-rank test for comparison of groups, and Cox proportional hazards regression model for regression analysis.
As data analysis proceeded, we identified a need to develop and apply more specialized statistical techniques that could provide estimates about the positive predictive value of the imaging if we could have biopsied all of the lesions. Accordingly, the expected number of true-positives was calculated using a hierarchical bayesian model-specifically, the β-binomial. 11 The results of imaging correlation with biopsy were considered a priori information, and a posteriori calculation was used to determine the best estimate (mean and 95%CI). This method is similar to a previous approach. 12 eAppendix 1 and eFigures 1-4 in the Supplement provide more details.
Results
A total of 158 patients were selected during the enrollment period ( Figure 1 ). Of these, 25 patients were excluded. Thus, a total of 133 patients were included (eTable 1 in the Supplement 
Patient Imaging Phenotypes
Four patient groups emerged, as described above. The concordant group (median, 5.5 lesions per patient) had significantly fewer lesions than all other groups (median of all other groups, 19.0; P < .001) (eTable 2 in the Supplement). Sixty-six (49.6%) patients had at least 1 lesion with absent or altered AR (AR 0 Glyc 1 ), including a median of 3.5 AR 0 Glyc 1 lesions per patient in the Glyc-predominant group and 2.0 lesions per patient in the mixed group. Baseline PSA expression was greatest for patients in the AR-predominant group, with a median level of 56.4 ng/mL com-pared with 21.2 ng/mL for the Glyc-predominant group (P =.02) (eFigure 7 in the Supplement).
Overall Survival Figure 3) . After excluding AR 0 Glyc 1 lesions, OS remained poor for patients with high AR 1 lesion counts (n = ≥10) (67.9 vs 175.6 weeks; P < .001) (eFigure 8 in the Supplement). On multivariate analysis using a Cox proportional hazards regression model, the 3 imaging phenotypes were found to be independent of each other and statistically significant when correlated with reduced survival. On multivariate analysis, the results indicated that each additional AR 0 Glyc 1 lesion increases the risk of death by 11% (HR, 1.11; 95% CI, 1.05-1.16; P<.001), AR 1 Glyc 1 lesion by 5% (HR, 1.05; 95% CI, 1.03-1.06; P<.001), and AR 1 Glyc 0 lesion by 3% (HR, 1.03; 95% CI, 1.00-1.05; P = .048) when the number of the other 2 lesion phenotypes is held constant. Baseline PSA level was not prognostic of OS (P = .06) (eFigure 7 in the Supplement).
Biopsy Data
To better understand the biologic significance of the positive images on a lesion-by-lesion basis, we obtained biopsies for confirmation of pathologic findings in 50 patients (37.6%) (eFigure 9 in the Supplement). A total of 59 biopsies were obtained (33 bone, 26 soft tissue), 2 of which were nondiagnostic. The remaining 57 biopsies were interpreted as follows: prostate cancer, 48 (84.2%); nonprostatic cancer, 3 (5.3%); inflammation, 1 (1.8%); and normal or benign tissue, 5 (8.8%). All 42 AR 1 lesions were prostate cancer, but 6 of 48 (12.5%) biopsies that were positive for prostate cancer were AR 0 Glyc 1 . Of 3 biopsies yielding a nonprostatic primary cancer, all were AR 0 Glyc 1 . One biopsy yielding inflammation was AR 0 Glyc 1 . Of the 5 biopsies reported as benign, 4 were Glyc nondetectable and all 5 were AR nondetectable (eTable 3i nt h eSupplement). A summary of the scan findings for bone and soft tissue is reported in eTable 4 in the Supplement. Twelve biopsy specimens were interpreted as consistent with poorly differentiated prostate cancer for which PSA immunohistochemistry was performed; 7 of the patient samples were AR 1 a n d5w e r eA R 0 . All 7 of the AR 1 scans were PSA positive, and 1 of 5 of the AR 0 scans were PSA positive. χ 2 Analysis indicated a significant association between AR 1 and PSA expression, a marker of differentiation in prostate cancer (P = .003 for chance association). In this study, we demonstrated intrapatient lesional diversity using molecular imaging of the primary driver of prostate cancer growth (ie, the AR), as well as Glyc, and showed that the 2 biochemical features appear to be largely independent of one another. 14 But heterogeneity has been the primary vulnerability of targeted therapy, and biopsying all lesions in a given patient is a practical impossibility. One possible solution is for imaging phenotypes to direct a biopsy to a particular lesion, which may provide specifics on how to treat a patient for improved response. As expected, the most common phenotype, AR 1 Glyc 1 , and the variant AR 1 Glyc 0 , together make up 96% of active mCRPC lesions. This finding is consistent with the importance of ARs to the development of mCRPC and as a target for the effectiveness of ARSi drugs. We hypothesize that, among the lesionimaging phenotypes we observed, the AR 0 Glyc 1 phenotype should provide clinically relevant information. Although producing a relatively small number of lesions overall when considered on a patient distribution basis, the AR 0 Glyc 1 phenotype represents 1 or more lesions in nearly half of patients. Since we hypothesize that AR 0 Glyc 1 lesions are likely to have altered or absent ARs, we have planned follow-up studies to evaluate the response to second-generation ARSi drugs in patients expressing this phenotype. Furthermore, the AR 0 Glyc 1 subset contains nonprostate cancer pathologies. Both lesion histologic factors will require additional alternative targeted therapies. Because patients may have either intrinsic or acquired resistance to ARSi drugs over a few months of treatment, a search for alternative targets and supplementary targeted therapies is under way. For example, a recent review of biopsy findings in 150 individuals with mCRPC revealed a higher-thananticipated mutational burden, raising the possibility of new treatment paradigms, including an array of non-AR-blocking targeted therapies. 14 The present study will serve as the baseline for future studies to determine whether individual patient groups or the presence of individual lesion subtypes may have distinct patterns of treatment response and/or survival; for example, the lack of detectable ARs (AR 0 Glyc 1 ) may correlate with poor response to ARSi drugs. Finally, we recognize that imaging is only 1 feature of prognostic modeling in prostate cancer. Separately, we are analyzing [ 
Biopsy Results as A Priori Predictors of Best Estimates for In Vivo Metabolic Heterogeneity
Limitations
We recognize that this study has potential limitations. Among the more important of these, only 2 molecular imaging tracers were used, namely, [
18 F]-FDG and [ 18 F]-FDHT, and although these tracers likely detected most lesions, it is possible that other active lesions were missed. In addition, lesions outside the PET/CT field of view (ie, above midskull or below upper thigh) may have been missed. Finally, in terms of tissue correlation, only a subset of lesions could practically be biopsied. This factor may have introduced a bias related to lesion accessibility, which limits generalization of the findings to all lesions.
Conclusions
In values, but also entails a method to project the information from the biopsied lesions to the unbiopsied ones to obtain statistically reliable estimates for clinically relevant quantities-e.g., the number of cancers found in a study. The Bayesian approach is ideally suited for this purpose since it allows the integration of information from various sources. Specifically, our Bayesian approach uses a sequential approach to the accumulation of information on a cancerous lesion.
To formalize this line of thinking, we denote by the probability that an imaged lesion is cancerous. Prior to the study, when we did not image any patients and did not obtain biopsy confirmation on some of the lesions, we did not have any information on what the value of might be other than the fact that it must be between 0 and 1. This lack of information can be represented by the following distribution (eFig. 1), which is also known as a uniform distribution or a beta distribution with parameters 1 and 1:
This distribution tells us that can take on any value between 0 and 1 with equal likelihood and any two intervals between 0 and 1 are equally likely to contain . This is why it is an appropriate tool to represent the lack of information on . We will denote this distribution by P( ).
The first pieces of information we have from the trial are the number of biopsied lesions (denoted by m) and the number of cancerous ones among them (denoted by X). We can now use the Bayes theorem to update our information on :
In this equation, "|" stands for "conditional on" or "given that we observed." The fundamental premise is that we start with P( ), observe X (which itself depends on as well as m), and update our knowledge about from P( ) to P( |X, m). The information we learn from X is represented by P(X| , m) and sometimes referred to as the likelihood function. P( ) is called the prior distribution since it represents the information prior to observing X, and P( |X, m) is called the posterior distribution since it represents the information after X is observed. The denominator on the right-hand side involving an integral may look complicated, but for conceptual purposes only plays the role of ensuring that P( |X, m) is a proper probability distribution, i.e., all the probabilities add to 1.
Using the soft tissue FDHT data as an example where all 42 of the biopsied sites had cancer, we can use the Bayes theorem as follows: X=m=42 and P( ) is a uniform distribution.
The information from the 42 biopsies translates the uniform distribution to that shown in eFigure 2, which is a beta distribution with parameters 41 and 1:
The term on the left-hand side is called the predictive distribution of Y; since it is unobserved, we are trying to predict what it might be. We do not want this prediction to be conditional on -we only want to depend on X and m, our only data points, and this is why is integrated out of the posterior distribution. In this setting, the predictive distribution turns out to be a beta-binomial distribution. In our case, the distribution of the number of cancerous lesions among the 2,059 unbiopsied sites now looks like this (eFig. 3): Although it looks like the posterior distribution, this is not a distribution for , but for Y, the number of cancerous lesions among the unbiopsied sites. Just as with the posterior distribution, the predictive distribution is also useful for calculating numbers such as the expected number of cancerous lesions, which is 2,014, the probability that at least 2,000 of the sites are cancer, which turns out to be 73%. 
eAppendix 2. Special Features of Study Design
Strengths of this study include the prospective nature of the study design, the long-term followup (almost two years for censored subjects), and the fact that 123 of the 133 were followed up to death (Fig. 1) .
The study was facilitated by an analysis platform and software that we co-developed with General Electric Medical Systems, PET VCAR. This methodology allowed us to assay all the metabolically active lesions in each patient admitted to the study cohort and to compare F18-FDG and F18-FDHT on a site-by-site basis using a novel fiduciary system that employs the companion CT scan of the PET/CT. 1 PET VCAR also facilitated image-guided biopsy in 51/133 patients. We employed Bayesian methods to obtain best estimates for imaging performance in the entire group of lesions, incorporating the biopsy results as prior data. ; effect of FDHT (non-radioactive) on the nuclear localization of an AR-GFP chimera (green) transfected into PC3 cells, which are normally AR-deficient (B). The nuclei are stained with DAPI (blue). As the concentration of androgen is increased, the AR-GFP (normally cytosolic) is activated and localizes to the nucleus and co-localizes with DAPI. A 3 nM dose of FDHT (near IC 50 ) is fully capable of pharmacological activation of AR. A 5 pM dose (a tracer dose far below pharmaceutical levels) cannot induce AR nuclear localization (the AR-GFP chimera is cytosolic).
F18-FDHT was developed through a collaboration between Katzenellenbogen and
Welch 2-4 (see eFig. 6). We have reported on the radiopharmacology in CRPC patients in prior studies; active F18-FDHT is rapidly cleared from the blood with a half-time of ~10 minutes. 5 Radiolabeled metabolites are produced in the liver and excreted into the gut, but also non-AR binding metabolites circulate in a protein-bound form for prolonged periods of time in the blood.
The ability to detect an active hormone receptor like AR through an imaging test is remarkable in itself, and FDHT pharmacology has fortunate features that make it quite valuable as a pharmacologic probe. First, it is fortunate that the metabolites do not interact with AR. Also, the low nanomolar affinity of FDHT as a binder to AR permits detecting a few thousand molecules at the cellular level. We have found that FDHT is an agonist, but that at the levels of localization in vivo, it is a true tracer in the sense of not exhibiting a key pharmacologic effect-namely transferring AR into the nucleus where it will interact with DNA (eFig. 10). F18-FDHT imaging requires careful attention to patient preparation to ensure that the patient is castrate at the time of imaging, with DHT levels < 50 pmoles/dl since competition with endogenous androgen will suppress uptake of the radiotracer. We have exploited these properties of F18-FDHT and applied them to the study of AR-targeted drugs such as enzalutamide 6 to document engagement with the target in vivo in patients, and also with apalutamide 7 to predict pharmacologically relevant dosing schedules that saturate the AR. Interestingly, among the tracer-avid lesions, only a very weak correlation is observed (r 2 = 0.001) with FDG/FDHT quantitative uptake (eFig. 5).
F18-FDG is the most widely used PET radiotracer in oncology for staging and monitoring treatment response. The current understanding, based on pathway activation studies, is that F18-FDG uptake is driven by glycolysis. 8 In prostate cancer, F18-FDG uptake tends to be greatest in more aggressive and metastatic tumors. Nonetheless, F18-FDG uptake is also highly responsive to hormonal suppression and is often negative in primary tumors, especially those with a low Gleason score, in hormonally responsive patients. Here, we applied F18-FDG in advanced tumors and documented that uptake levels (as shown in SUVmax values) are inversely
